Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Apr 2025 According to an Anavex Life Sciences Media Release, data from this study were presented at the AD/PDTM 2025 Conference.
05 Apr 2025 Results presented in an Anavex Life Sciences Media Release.
24 Dec 2024 According to an Anavex Life Sciences media release, the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for blarcamesine for Alzheimers disease. The MAA is supported by data from the ANAVEX2-73-AD-004 trial and its up to 144 week open-label-extension ATTENTION-AD ANAVEX2-73-AD-EP-004 trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com